Inactive Instrument

Lightlake Therapeutics Stock OTC Bulletin Board

US53224T1051

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2023	Indivior completes acquisition of Opiant Pharmaceuticals	AN
2023	Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	MT

Latest news about Lightlake Therapeutics

Indivior completes acquisition of Opiant Pharmaceuticals	23-03-02	AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	23-03-02	MT
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index	23-03-02	CI
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index	23-03-02	CI
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	23-03-01	CI
Transcript : Opiant Pharmaceuticals, Inc. - Shareholder/Analyst Call	23-03-01
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	23-02-07	MT
Indivior announces expiry of waiting period for Opiant purchase	23-02-06	AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	23-02-06	MT
Indivior Nears Acquisition of Opiant Pharmaceuticals	23-02-06	MT
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals	23-01-26	RE
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	23-01-20	MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	23-01-19	CI
Insider Sell: Opiant Pharmaceuticals	23-01-05	MT
Opiant Pharmaceuticals Completes Rolling Submission of New Drug Application for Potential Opioid Overdose Drug	22-11-23	MT

More news

Analyst Recommendations on Lightlake Therapeutics

Oppenheimer Initiates Coverage on Opiant Pharmaceuticals With Outperform Rating, $42 Price Target

21-12-09

More recommendations

Press releases Lightlake Therapeutics

OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-02	AQ
OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-03-01	AQ
OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	23-02-27	AQ
OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-07	AQ
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	23-02-07	GL

More press releases

News in other languages on Lightlake Therapeutics

Bolsa de Madrid: Jerome vuelve en la segunda semana	23-02-07
Jerome revient en deuxième semaine	23-02-07
En Direct des Marchés : BNP Paribas, TotalEnergies, L'Oréal, Scor, Casino, CVS, Bayer, Siemens, BP...	23-02-07
MÄRKTE USA/Leichter - Anleger agieren zurückhaltend	22-11-14
MÄRKTE USA/Uneinheitlich - Anleger sind vorsichtig	22-11-14

More news

Managers and Directors - Lightlake Therapeutics

Managers	Title	Age	Since
Ryan Preblick DFI	Director of Finance/CFO	-	-

More insiders

Opiant Pharmaceuticals, Inc., is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Its lead development product include OPNT003. The Company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and Acute Cannabinoid Overdose (ACO). The Company also is focused on other treatment opportunities within the addiction and drug overdose field.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B